Synergistic antinociceptive interaction of Syzygium aromaticum or Rosmarinus officinalis coadministered with ketorolac in rats

Beltrán-Villalobos, Karla Lyzet; Déciga-Campos, Myrna; Aguilar-Mariscal, Hidemí; González-Trujano, María Eva; Martínez-Salazar, María Fernanda; Ramírez-Cisneros, M. Ángeles; Rios, Marı́a Yolanda; López‐Muñoz, Francisco

doi:10.1016/j.biopha.2017.07.166

Cited by 28 publications

(35 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The synergistic and antinociceptive activities of R. officinalis L. ethanol extract was reported in a study conducted in Wistar rats [77]. The animals were previously treated with plant extract, phytocompounds (ursolic acid and oleanolic acid), ketorolac, an NSAID, and ketorolac associated with plant products.…”

Section: Antinociceptive Effectmentioning

confidence: 99%

“…Antinociceptive activity can be increased with synergism between NSAIDs and plant products, such as extracts and phytocompounds from R. officinalis L. Thus, doses of analgesics could be reduced, as demonstrated by Beltrán-Villalobos et al [77] which treated rats with ketorolac associated with R. officinalis L.…”

Section: Antinociceptive Effectmentioning

confidence: 99%

“…In this Review, some pharmacological effects of products from R. officinalis L. were shown. These effects were widely demonstrated on diverse types of disorders including (a) cardiac remodeling after myocardial infarction [47]; (b) body weight and dyslipidemia [60]; (c) cerebral ischemia [71]; (d) pain [77]; (e) infections [91]; (f) hepato-nephrotoxicity by lead [123]; (g) stress and anxiety [132]; and (h) tumor cells proliferation [91, 152–154]. Thus, with this study, it was possible to verify the benefits of R. officinalis L. on specific health problems that can affect many people around the world.…”

Section: Final Considerations and Conclusionmentioning

confidence: 99%

“…Plant products administrated in association with ketorolac improved the antinociceptive effect. Thus, this study showed that products from R. officinalis L. did not affect the efficiency of an allopathic drug, in contrast, they potentialized the pain control, in a complementary manner [77].…”

Section: Final Considerations and Conclusionmentioning

confidence: 99%

“…Absence of dyslipidemia effectb. Reduction of acute ischemic stroke lesion[71]Antinociceptive effectEthanolic extractPain control[77]Mono- and polymicrobial biofilms reductionGlycolic extracta. Antimicrobial effectb.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Rosmarinus officinalis L. (rosemary) as therapeutic and prophylactic agent

2019

View full text Add to dashboard Cite

Rosmarinus officinalis L. (rosemary) is a medicinal plant native to the Mediterranean region and cultivated around the world. Besides the therapeutic purpose, it is commonly used as a condiment and food preservative. R. officinalis L. is constituted by bioactive molecules, the phytocompounds, responsible for implement several pharmacological activities, such as anti-inflammatory, antioxidant, antimicrobial, antiproliferative, antitumor and protective, inhibitory and attenuating activities. Thus, in vivo and in vitro studies were presented in this Review, approaching the therapeutic and prophylactic effects of R. officinalis L. on some physiological disorders caused by biochemical, chemical or biological agents. In this way, methodology, mechanisms, results, and conclusions were described. The main objective of this study was showing that plant products could be equivalent to the available medicines.

show abstract

Section: Antinociceptive Effectmentioning

confidence: 99%

Section: Antinociceptive Effectmentioning

confidence: 99%

Section: Final Considerations and Conclusionmentioning

confidence: 99%

Section: Final Considerations and Conclusionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Rosmarinus officinalis L. (rosemary) as therapeutic and prophylactic agent

2019

View full text Add to dashboard Cite

show abstract

Synergistic interaction between 4‐allyl‐1‐hydroxy‐2‐methoxybenzene (eugenol) and diclofenac: An isobolograpic analysis in Wistar rats

González‐Lugo¹,

Pozos‐Guillén

Ponce‐Peña³

et al. 2020

Drug Development Research

View full text Add to dashboard Cite

Clinical and preclinical research that contributes pain palliation has suggested that drugs favor the expected effects and minimize the adverse effects. Among the most widely used strategies is the combination of analgesic drugs among those in the same group, with those in another group of analgesics or with co-adjuvants (nonanalgesic drugs or elements of traditional medicine). This work aims to evaluate the interaction between eugenol (EUG) and diclofenac (DFC) on nociception in the presence of a noxious stimulus through the formalin test and isobolographic analysis. The results indicate that EUG, DFC, or the combination of both produce an antinociceptive effect in rodents (p ≤ 0.05). Local co-administration of EUG and DFC gave a theoretical effective dose (Z add) 2,936.27 ± 155.33 μg/kg (p ≤ 0.05) significantly higher as compared to the effective experimental doses (Z mix) of 866.89 ± 0.02 μg/kg in phase 1 and 292.88 ± 0.05 μg/kg in phase 2, with an interaction index of 0.29 and 0.09, respectively. These data allow concluding that the interaction derived from the joint administration of EUG and DFC, in the rodent at a local level, is synergistic.

show abstract